Book
Bronchial Asthma
- Abbreviations
|
Abbreviation |
Meaning |
|
ABPA |
Allergic bronchopulmonary aspergillosis |
|
ACQ |
Asthma Control Questionnaire |
|
ACQ-5 |
Five-item Asthma Control Questionnaire |
|
ACT |
Asthma Control Test |
|
AERD |
Aspirin-exacerbated respiratory disease |
|
AGREE II |
Appraisal of Guidelines for Research and Evaluation II |
|
AIR |
Anti-inflammatory reliever: as-needed low-dose ICS-formoterol (ICS-formoterol only) |
|
APGAR |
Asthma APGAR tool: Activities, Persistent triGgers, Asthma medications, Response to therapy |
|
BEC |
Blood eosinophil count |
|
BMI |
Body mass index |
|
CAAT |
Chronic Airways Assessment Test |
|
COPD |
Chronic obstructive pulmonary disease |
|
COX-2 |
Cyclooxygenase-2 |
|
CPAP |
Continuous positive airway pressure |
|
CRSwNP |
Chronic rhinosinusitis with nasal polyps |
|
CT |
Computed tomography |
|
DLCO |
Diffusing capacity of the lung for carbon monoxide |
|
DPI |
Dry-powder inhaler |
|
ED |
Emergency department |
|
EGPA |
Eosinophilic granulomatosis with polyangiitis |
|
EIB |
Exercise-induced bronchoconstriction |
|
ER |
Emergency room |
|
ESSB |
Egyptian Scientific Society of Bronchology |
|
FeNO |
Fractional concentration of exhaled nitric oxide |
|
FEV₁ |
Forced expiratory volume in 1 second |
|
FVC |
Forced vital capacity |
|
GERD |
Gastroesophageal reflux disease |
|
GINA |
Global Initiative for Asthma |
|
GRADE |
Grading of Recommendations Assessment, Development and Evaluation |
|
HFA |
Hydrofluoroalkane propellant |
|
HRCT |
High-resolution computed tomography |
|
ICS |
Inhaled corticosteroid |
|
ICS-LABA |
Combination of an inhaled corticosteroid and a long-acting β₂-agonist |
|
ICU |
Intensive care unit |
|
IgE |
Immunoglobulin E |
|
IL-4 |
Interleukin-4 |
|
IL-4Rα |
Interleukin-4 receptor alpha |
|
IL-5 |
Interleukin-5 |
|
IL-5Rα |
Interleukin-5 receptor alpha |
|
IL-13 |
Interleukin-13 |
|
IV |
Intravenous |
|
LABA |
Long-acting β₂-agonist |
|
LAMA |
Long-acting muscarinic antagonist |
|
LTRA |
Leukotriene receptor antagonist |
|
MART |
Maintenance-and-reliever therapy (with combination ICS-formoterol) |
|
mcg |
Microgram |
|
MID |
Minimal important difference |
|
MoH, MoHP |
Ministry of Health and Population (Egypt) |
|
NAEPP |
National Asthma Education and Prevention Program (USA) |
|
NSAIDs |
Non-steroidal anti-inflammatory drugs |
|
O₂ |
Oxygen |
|
OCS |
Oral corticosteroids |
|
OSA |
Obstructive sleep apnea |
|
PEF |
Peak expiratory flow |
|
PICO |
Population, Intervention, Comparator, Outcomes |
|
pMDI |
Pressurized metered-dose inhaler |
|
PO |
By mouth (per os) |
|
ppb |
Parts per billion |
|
PPI |
Proton pump inhibitor |
|
SABA |
Short-acting β₂-agonist |
|
SC |
Subcutaneous |
|
SCIT |
Subcutaneous immunotherapy |
|
SLIT |
Sublingual immunotherapy |
|
SpO₂ |
Peripheral oxygen saturation measured by pulse oximetry |
|
STAT |
Immediately |
|
WHO |
World Health Organization |
